Nov 30, 2025, 14:49
Talha Badar ASH25 Key Abstracts to Watch in Acute Lymphoblastic Leukemia
Talha Badar, Hematologist-Oncologist at Mayo Clinic Comprehensive Cancer Center, posted on X:
“ASH25 Key abstracts to watch in acute lymphoblastic leukemia
Overall Takeaways — ASH 2025 ALL Landscape
Rapid movement toward chemo-free or chemo-lite regimens, especially in Ph+ ALL.
TKI + immunotherapy (blina / InO) emerging as new standard-contenders.
CAR-T earlier in therapy (CR1 consolidation and frontline).
Expanding roles for bispecifics and venetoclax-based combinations in R/R ALL.
MRD (especially NGS-MRD) central to future risk-adapted strategies.”
Discover the latest in Hemostasis Today.
-
Dec 1, 2025, 15:31Register for the Women with Bleeding Disorders Summit 2026! – EHC
-
Dec 1, 2025, 15:30Jim Hoffman on a Critical Question: Should We Track NETosis and Use Blood Purification in Heart Failure?
-
Dec 1, 2025, 15:27It’s Time for November’s Learning Update! – ISBT
-
Dec 1, 2025, 15:26Marilena Vrana: “Meet Me in Milan” Should Be the Global Plasma Community’s Pass-Along Catchphrase
-
Dec 1, 2025, 15:25Maartje van den Biggelaar: LSBR Awarded Our Consortium the LSBR Anniversary Grant of €1.6 Million to Launch HemoTwin-BD
-
Dec 1, 2025, 15:24Dr Aaron Akpu Philip on the Front Lines: Supporting the National Blood Drive with Lifeblood and AIMA
-
Dec 1, 2025, 15:23Anas Nasir: A Free Barcode Generator for Transfusion Training
-
Dec 1, 2025, 15:22Rahul Bhargava: Multiple Myeloma – the Poster Child of Innovation
-
Dec 1, 2025, 15:22Abdul Mannan: Why AML inv(16) Isn’t Just “Favourable”